{
  "drug_name": "Imipenem-cilastatin",
  "tradename": "Primaxin, Tienam",
  "usage_and_dosing": {
    "general": [
      "Imipenem-cilastatin is a carbapenem with a broad spectrum of activity that includes:",
      "Aerobic and anaerobic gram-negative bacilli.",
      "Aerobic gram-negative bacilli that produce extended-spectrum beta-lactamases (ESBL).",
      "Notable absence of activity vs. MRSA, E. faecium, vancomycin-resistant enterococci, and Stenotrophomonas spp.",
      "Cilastatin blocks enzymatic degradation of imipenem by renal dehydropeptidase on brush border of proximal convoluted tubule, decreasing risk of proximal tubule toxicity.",
      "Wide variety of FDA-approved indications.",
      "An alternative antibiotic for drug resistant genotypes.",
      "Because of its relative instability in solution, imipenem-cilastatin is not suitable for outpatient prolonged infusion therapy.",
      "For infection due to P. aeruginosa, increase dose to 3-4 gm/day (divided q6-8h). Extended infusion of carbapenems may be more efficacious (there are stability issues; see Continuous, Extended Infusion Dosing).",
      "Allergy",
      "For allergy considerations, see Carbapenems, Overview.",
      "See protocol for desensitization."
    ]
  },
  "antimicrobial_stewardship": {
    "enterobacterales_susceptibility": "The current Enterobacterales susceptibility breakpoint of ≤1 µg/mL for carbapenems significantly reduces rates of susceptibility for certain species to imipenem-cilastatin compared to other carbapenems, for which susceptibility rates are largely unaffected (Can J Infect Dis Med Microbiol 2014;25:285; J Antimicrob Chemother 2011;66:2671). The mechanism of this differential susceptibility is unknown but may be due to differences in binding affinity to target penicillin binding proteins.",
    "affected_organisms": {
      "proteus_spp": "100% vs. 65-85%",
      "morganella_morganii": "100% vs. 20-40%",
      "providencia_spp": "100% vs. 70%",
      "serratia_spp": "99% vs. 93%"
    },
    "meropenem_surrogate": "Meropenem susceptibility should not be relied upon as a surrogate to predict susceptibility to Imipenem."
  },
  "adult_dose": {
    "usual_dose": "500 mg IV q6h, OR 1 gm IV q8h",
    "intermediate_susceptibility": "1 gm IV q6h"
  },
  "pediatric_dose": {
    "age_lt_1_wk_wt_ge_1_5_kg": "25 mg/kg q12h",
    "age_1_wk_to_4_wks_wt_ge_1_5_kg": "25 mg/kg q8h",
    "age_4_wks_to_3_mon_wt_ge_1_5_kg": "25 mg/kg q6h",
    "age_ge_3_mon": "15-25 mg/kg q6h",
    "max_day": "4 gm"
  },
  "renal_adjustment": {
    "half_life_normal": "1",
    "half_life_esrd": "4",
    "dose_renal_function_normal": "Variable",
    "crcl_or_egfr": {
      "target_500mg_q6h": "CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 400 mg q6h. CrCl 30 to <60: 300 mg q6h. CrCl 15 to <30: 200 mg q6h",
      "target_1gm_q8h": "CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 500 mg q6h. CrCl 30 to <60: 500 mg q8h. CrCl 15 to <30: 500 mg q12h",
      "target_1gm_q6h": "CrCl ≥90: No dosage adjustment. CrCl 60 to <90: 750 mg q8h. CrCl 30 to <60: 500 mg q6h. CrCl 15 to <30: 500 mg q12h"
    },
    "hemodialysis": {
        "target_500mg_q6h": "200 mg q6h (dose AD)",
        "target_1gm_q8h": "500 mg q12h (dose AD)",
        "target_1gm_q6h": "500 mg q12h (dose AD)"
    },
    "capd": "No data",
    "crrt": "0.5-1 gm q6h (varies w/MIC, effluent rate) 47"
  },
  "hepatic_adjustment": {
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "No dosage adjustment"
  },
  "other_adjustment": [
    "Obesity: See Obesity Dosing Adjustments.",
    "ECMO: See ECMO Drug Dosing Adjustment."
  ],
  "adverse_effects": [
    "GI (nausea, vomiting, diarrhea, C. difficile infection).",
    "In patients who develop nausea during the infusion, the rate of infusion may be slowed.",
    "Hypersensitivity (rash, urticaria, anaphylaxis)",
    "Local phlebitis",
    "Hematologic: neutropenia, eosinophilia, thrombocytopenia",
    "Increased LFTs",
    "Seizure risk, see Carbapenems, Overview."
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans; some evidence of maternal and fetal toxicity in animals. Considered safe for use in pregnant patients.",
    "lactation": "Safe, monitor infant for GI toxicity",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {
    "preferred": [
      "Bacteroides fragilis",
      "E. coli, extended spectrum beta lactamase producer (ESBL)",
      "Nocardia sp.",
      "Resistant (ESBL) oxytoca, pneumoniae, variicola"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "40 (500 mg IV, SD)",
    "peak_urine_conc_ug_ml": "No data",
    "protein_binding_percent": "15-25",
    "volume_of_distribution_vd_l_kg": "0.23-0.31 L/kg",
    "avg_serum_half_life_hr": "1",
    "elimination": "Renal",
    "bile_penetration_percent": "Minimal",
    "csf_blood_percent": "8.5",
    "therapeutic_levels_in_csf": "Possibly 9",
    "auc_ug_hr_ml": "42.2 (500 mg IV, 0-inf)"
  },
  "enzyme_transporter_mediated_interactions": {
      "cyp450s_substrate": [],
      "transporters_substrate": "Imipenem: OAT1, OAT3, Cilastatin: OAT1, OAT3",
      "ugts_substrate": [],
      "cyp450s_inhibited": [],
      "transporters_inhibited": [],
      "ugts_inhibited": [],
      "cyp450s_induced": [],
      "transporters_induced": [],
      "ugts_induced": [],
      "impact_on_serum_drug_concentrations": "None expected"
  },
  "major_drug_interactions": [
      {
          "drug": "BCG",
          "effect": "↓ effectiveness of BCG",
          "management": "Avoid co-administration"
      },
      {
          "drug": "Ganciclovir",
          "effect": "↑ seizure risk",
          "management": "Monitor"
      },
      {
          "drug": "Probenecid",
          "effect": "↑ imipenem",
          "management": "Monitor, adjust dosage"
      },
      {
          "drug": "Valganciclovir",
          "effect": "↑ seizure risk",
          "management": "Monitor"
      },
      {
          "drug": "Valproic acid",
          "effect": "↓ valproic acid",
          "management": "Monitor, adjust dosage"
      }
  ]
}
